# Can You Take a GLP-1 With a Heart Pump? 141 Pairs, and No Effect Sizes | This GLP A matched cohort of 141 pairs with left ventricular assist devices reported less driveline infection and lower mortality with prior GLP-1 exposure | but published no effect sizes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With a Heart Pump? 141 Pairs, and No Effect Sizes Fewer driveline infections, lower mortality and more transplants, all of it reported as a direction with no magnitude attached, and all of it in people whose GLP-1 prescription predates the operation. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read What the paper reports · driveline infection, 1 year · lower · — no figure · mortality, 3 years · lower · — no figure · transplant listing, 3 years · higher · — no figure · heart transplantation, 3 years · higher · — no figure · 141 matched pairs. No hazard ratios or intervals published. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Among 527 people with obesity who received a durable left ventricular assist device, 231 had documented GLP-1 exposure before implantation; 141 pairs were matched. - The abstract reports lower driveline infection at one year, and at three years lower mortality with more transplant listing and more transplantation. - No hazard ratios, confidence intervals or percentages accompany any of those outcomes. - Exposure was before the pump was implanted, which selects for people already well enough and engaged enough to be on the drug. There is one study, it covers 141 matched pairs, and it publishes no effect size for any outcome, so the answer is that nobody can tell you how much difference it makes. A left ventricular assist device is a mechanical pump implanted when a heart is failing badly enough to need one, often as a bridge to transplant. Obesity complicates the surgery, increases infection around the driveline that exits the skin, and at many centers blocks transplant listing outright. Among 527 people with obesity who received one, 231 had documented GLP-1 exposure before implantation, and 141 pairs were matched[\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump#ref-1). It sits among the growing set of results in populations trials never enroll, alongside [the sickle cell cohort](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease). The reported direction is favorable across the board: fewer driveline infections at one year, and at three years lower mortality along with more transplant listings and more transplants performed. In a population this sick, all of those would be meaningful. None of those outcomes comes with a number The abstract states directions and no effect sizes — no hazard ratios, no confidence intervals, no percentages for any outcome. That is unusual, and it means a reader cannot tell whether the mortality difference was large or marginal, or how precisely anything was estimated. This article reports the absence rather than filling it, because inventing magnitudes the paper did not publish is not an option. The exposure definition carries the heavier problem. Patients qualified by having a GLP-1 prescription _before_ implantation, so the comparison is between people who arrived at major cardiac surgery already on one and people who did not. Being on a GLP-1 drug beforehand means being stable enough to have been started on it, engaged enough to have continued, and managed in advance rather than arriving in crisis. In a group where reaching elective implantation in good condition largely determines what follows, that is close to selecting on the outcome — the same structure flagged in [the dialysis cohort](https://thisglp.com/research/dialysis-the-evidence-base-just-grew). One finding deserves separating from the rest because its mechanism is probably not cardiac at all. Transplant listing is a committee decision, and a BMI ceiling is a common explicit criterion. More listings among GLP-1 users may be recording that people crossed a threshold on a chart rather than that their hearts improved. That is a genuine and important benefit, because access to transplantation is the thing that changes survival here. It is still a different claim from the drug treating heart failure, which is examined on its own terms in [the heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure) and [the rheumatoid arthritis cohort](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis). A second cohort in a comparably sick population shows what this one is missing. Among patients with end-stage kidney disease on dialysis, GLP-1 use was studied for hospitalization and mortality with published risk estimates attached [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump#ref-2), which is what lets a reader judge whether a difference is large or marginal. Both studies select people well enough to have been started on the drug, and only one of them lets you see how big the resulting gap was. The authors describe their findings as observational and hypothesis-generating and ask for prospective evaluation, which is the right conclusion from 141 pairs with no published effect sizes. What it establishes is that the question deserves asking properly, in a population where weight is not a cosmetic concern but a gate to the treatment that would save them. ## Frequently asked How large were the benefits? Unstated. The paper reports directions — lower infection, lower mortality, more transplants — without hazard ratios, confidence intervals or percentages for any outcome. Were patients taking the drug after their implant? Exposure was defined before implantation. The comparison is between people who arrived at surgery already on a GLP-1 drug and people who did not, which selects for being stable and engaged with care beforehand. Why did more patients reach transplant? Possibly because obesity is an explicit barrier to transplant listing at many centers, so weight loss may move someone across a threshold. That is a real benefit, but a different mechanism from improving the heart itself. ## Sources 1. \[1\] Divya A, Dalal N, Yoshida Y, Kanwar M, Catarino P, D'Alessandro D (2026). Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study ASAIO Journal. [PMID 42497207](https://pubmed.ncbi.nlm.nih.gov/42497207/) 2. \[2\] Karpinski S, Qazi R, Bjordahl T, Sibbel S, Weinhandl E, Tentori F, Brunelli SM (2026). Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease Clinical Journal of the American Society of Nephrology. [PMID 42640716](https://pubmed.ncbi.nlm.nih.gov/42640716/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)